Moderna mRESVIA RSV vaccine approved by MHRA

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved an mRNA respiratory syncytial virus (RSV) vaccine (brand name mRESVIA) to protect patients aged 60 and over against lower respiratory tract disease caused by RSV.

The new marketing authorization was granted to a subsidiary of US mRNA specialist Moderna (Nasdaq: MRNA), which has high hopes for the vaccine and earlier this month reported that mRESVIA generated sales of $25 million in 2024. However, competitors Arexvy, from GSK (LSE: GSK), and Pfizer’s (NYSE: PFE) Abrysvo, have a headstart on mRESVIA.

"The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, chief executive of Moderna, who noted that its RSV vaccine will be manufactured at the Moderna Innovation and Technology Centre in Oxfordshire, which will be fully operational later this year.